路冬梅｜济南大学｜学者主页

2026

TRIM28 orchestrates SUMO-ubiquitin crosstalk to stabilize PPARG and drive bladder cancer progression

Xuefeng Fan, Ze-Xuan Li, Qiong-Qiong Gao, Peizhen Huang, Zhe-Yu Li, Dongmei Lu, Lei Wang, Ping Xiang, Tao Huang, Dexin Shen, Jun Xiao

Cell Death and Disease

DOI

2026

Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study

Shuang Huang, Feng Liu, Song Qu, Lisha Chen, Ping Zhou, Shen-Hong Qu, Xiao-Hong Ai, Yong Chen, Mei-Lian Liu, Rensheng Wang, Kelvin Chan, Peng Zhang, Chun-Hong Hu, J. Wen, Jian Zhang, Qinye Lin, Xiao-Jiang Li, Kang-Sheng Gu, Lisha Xiang, Dongxia Wang, Jingao Li, Daren Lin, Desheng Hu, Jian-Wu Ding, Siyang Wang, Xiao-Ming Huang, Lin Wang, Feng Jin, D. Pfister, M. Mak, P. D. de Marchi, Yi Jiang, Haihua Yang, Xiao-Ye Hu, T. Liu, Dehua Wu, A. Shreenivas, T. B. de Oliveira, Carlos Eduardo Baston Silva, G. V. Alves, Xian-Ming Li, Zhifang Yao, Dongmei Lu, Mingxiu Hu, Z. Wang, Bai-Yong Li, Michelle Y. Xia, Xiao-Zhong Chen, Chao-Su Hu, Ting-Ting Xu

Signal Transduction and Targeted Therapy

DOI

2026

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China.

Shun Lu, Baogang Liu, Yongzhong Luo, Long-Hua Sun, Lin Wu, Zheng-Xiang Han, Yun Fan, Yan-Qiu Zhao, Xing-Ya Li, Haipeng Xu, Xiang-Jiao Meng, Ying Liu, Zhi-Ye Zhang, Hui Luo, Xue-Lei Ma, Xue-Zhen Ma, Qin Shi, Zhong-Min Zhang, Run-Xiang Yang, Ping Wang, P. Pan, Xiao-Hong Ai, Jie Li, X. Pu, Zhi-Wu Wang, J. Fang, M. He, Yong He, Shu-Liang Guo, Juan Li, Hongbiao Wang, Junqiang Zhang, Q. Chu, Xue-Wen Liu, Shen-Peng Ying, Hongcheng Wu, Hongmei Sun, Yinghua Ji, Minghao Zhou, Chao Cao, Ke-Jing Tang, Zheng-Guo Li, Dairong Li, Zhihong Zhang, Jian-Ya Zhou, Hong-Zhong Yang, Ying-Ying Du, Hui Yang, Jiankai Shi, Hua-Lin Chen, Zhiwei Chen, Wen-Ting Li, Dongmei Lu, Mingxiu Hu, Z. Wang, Bai-Yong Li, Michelle Y. Xia

The Lancet

DOI

2026

The impact of body mass index on the treatment response to neoadjuvant chemotherapy in patients with breast cancer: A systematic review and meta-analysis

Lirong Zhang, Dongmei Lu, Pan Geng, Gang Chen, Ya-Qing Wang, Juan-Qin Niu

Tumori

DOI

2026

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.

W. Fang, Yuan-Yuan Zhao, Yongzhong Luo, Run-Xiang Yang, Yan Huang, Zhi-Yong He, Hui Zhao, Ming-Jun Li, Kai Li, Qi-Bin Song, Xiao-bo Du, Yulan Sun, Wei Li, Long-Hua Sun, Zhi-Yu Wang, Kunning Yang, Yun Fan, Baogang Liu, Hong-Yun Zhao, Ying Hu, Li Jia, Shen Xu, T. Yi, Dong-Qing Lv, Hai-Tao Lan, Meng-Xia Li, Wenhua Liang, Yong-Sheng Wang, Hui Yang, Yuming Jia, Yuan Chen, Junguo Lu, Mei-Qi Shi, Chun-Ling Liu, Ming Zhou, Jian-Ya Zhou, Xian-Ling Liu, N. Zhou, Ming He, Xiao-Rong Dong, Hua-Lin Chen, Yong-Xing Chen, Hai-Chuan Su, Xiao-Lin Li, Zhihong Zhang, Lei Yang, Ying Liu, Li-Kun Chen, X. Hou, Yu Zhang, Jun Guo, Ruiqiang Ma, Hong Lu, Di Wu, W. Feng, Wen Li, Jianan Huang, Yan Wang, Xia Song, Jie-Wen Peng, Laiyu Liu, Yu-Biao Guo, Wen-Ting Li, Meng-Ying Xia, Dongmei Lu, Mingxiu Hu, Z. Wang, Bai-Yong Li, Michelle Y. Xia, Li Zhang

Journal of the American Medical Association (JAMA)

DOI

2026

Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial

Yang Sun, Hong-Ying Yang, Jing Wang, Hanmei Lou, Dan Li, Ke Wang, Hui Zhang, Tao Wu, Yu-Zhi Li, Chunyan Wang, Gui-Ling Li, Yifeng Wang, Da-Peng Li, Ying Tang, M. Pan, Hong-Yi Cai, Wei-Hu Wang, Bing-Yi Yang, Hua Qian, Qiu-Hong Tian, Desheng Yao, Ying Cheng, Bing Wei, Xiu-Min Li, Tao Wang, Min Hao, Xiaohong Wang, Tie-Jun Wang, Chang Liu, Hong Zhu, Lijing Zhu, Xian-Ling Liu, Yun-Xia Li, Li-Hong Chen, Qingshan Li, Xiaojian Yan, Fei Wang, Hong-Bing Cai, Yun-Yan Zhang, Zhi-Qing Liang, Funan Liu, Yi Huang, B. Xia, Peng-Peng Qu, Genhai Zhu, Youguo Chen, Kun Song, Meili Sun, Zheng-Zheng Chen, Qiang Zhou, Lina Hu, G. Abulizi, Hong-Yan Guo, Si-Hai Liao, Yijing Ye, P. Yan, Q. Tang, Guoping Sun, Ting Liu, Dongmei Lu, Mingxiu Hu, Z. Wang, Bai-Yong Li, Michelle Y. Xia, Xiao-Hua Wu

Nature Communications

DOI

2025

CDCA3-MYC positive feedback loop promotes bladder cancer progression via ENO1-mediated glycolysis

Dexin Shen, Xiang Yu, Xue Fan, Yu Liang, Dongmei Lu, Zong-Pan Ke, Lei Wang, Ping Xiang, Jun Xiao

Journal of experimental & clinical cancer research : CR

DOI

2025

Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.

Anwen Xiong, Lei Wang, Jian-Hua Chen, Lin Wu, Bao-Gang Liu, Jun Yao, Hua Zhong, Jie Li, Ying Cheng, Yulan Sun, Hui-Ting Ge, Ji-Fang Yao, Qingmei Shi, Ming Zhou, Bolin Chen, Zheng-Xiang Han, Jin-Liang Wang, Q. Bu, Yan-Qiu Zhao, Jun-Qiang Chen, Li-Gong Nie, Gaofeng Li, Xing-Ya Li, Xinmin Yu, Yinghua Ji, Da-Qiang Sun, Xiao-Hong Ai, Q. Chu, Yu Lin, Jiqing Hao, Ding-Zhi Huang, Cheng-Zhi Zhou, Jinlu Shan, Hong-Zhong Yang, Xue-Wen Liu, Jing Wang, Yan-Hong Shang, Xiao Mei, Jie Yang, Dongmei Lu, Mingxiu Hu, Z. Wang, Bai-Yong Li, Michelle Y. Xia, Cai-Cun Zhou

The Lancet

DOI

2025

Cadonilimab in advanced cervical cancer: the COMPASSION-16 trial - Authors' reply.

Ting Liu, Dongmei Lu, Xiaohua Wu

The Lancet

DOI

2025

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial.

Zhi-Wei Chen, Fang Yang, Zhou Jiang, Long-Hua Sun, Lin Wu, Zheng-Xiang Han, Yun Fan, Yan-Qiu Zhao, Xing-Ya Li, Haipeng Xu, Xiang-Jiao Meng, Ying Liu, Zhi-Ye Zhang, Hui Luo, Xue-Zhen Ma, Xue-Zhen Ma, Qin Shi, Zhong-Min Zhang, Run-Xiang Yang, Pingli Wang, P. Pan, Xiao-Hong Ai, Jie Li, X. Pu, Zhi-Wu Wang, Jian Fang, Ming He, Yong He, Shu-Liang Guo, Juan Li, Hongbiao Wang, Junqiang Zhang, Q. Chu, Xue-Wen Liu, Shen-Peng Ying, Hongcheng Wu, Hong Sun, Yinghua Ji, Ming Zhou, Chao Cao, Ke-Jing Tang, Zheng-Guo Li, Dairong Li, Zhihong Zhang, Jian-Ya Zhou, Hong-Zhong Yang, Yingying Du, Hui Yang, Jian Shi, Hua-Lin Chen, Wen-Ting Li, Dongmei Lu, Mingxiu Hu, Zhongmin Maxwell Wang, Bai-Yong Li, Michelle Y. Xia, Shun Lu

The Lancet

DOI

2025

Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)

Chao-Su Hu, Xiao-Zhong Chen, Ting-Ting Xu, Shuang Huang, Feng Liu, Song Qu, Lisha Chen, P. Zhou, Shen-Hong Qu, Xiao-Hong Ai, Yong Chen, Mei-Lian Liu, Rensheng Wang, Kelvin K. W. Chan, Peng Zhang, Chun-Hong Hu, J. Wen, Jian Zhang, Qin Lin, Xiao-Jiang Li, Kang-Sheng Gu, Li Xiang, Dongxia Wang, Jin-Gao Li, Daren Lin, Desheng Hu, Jianwu Ding, Siyang Wang, Xiao-Ming Huang, Lin Wang, Feng Jin, D. Pfister, M. Mak, Pedro Rafael Martins de Marchi, Yi Jiang, Hai-Hua Yang, Xiao-Ye Hu, Tian-Run Liu, Dehua Wu, A. Shreenivas, Thiago Bueno de-Oliveira, C. E. Baston Silva, G. Alves, Xian-Ming Li, Zhifang Yao, Dongmei Lu, Mingxiu Hu, Z. Wang, Bai-Yong Li, Michelle Y. Xia

Cancer Research

DOI

2025

First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial

Lin Shen, Yan-Qiao Zhang, Zi-Yu Li, Xiao-Tian Zhang, Xiang-Yu Gao, Bo Liu, Yu-Sheng Wang, Y. Ba, Ning Li, Ruixing Zhang, Jing-Dong Zhang, Ye Chen, Jian Chen, Mingzhu Huang, Yang Fu, Mu-Lin Liu, Zheng Liu, Jun Zhao, Wei Li, Jia Wei, Changzheng Li, Nong Xu, Zengqing Guo, Bang-Wei Cao, Lian Liu, Peng Nie, Lixin Wan, Li-Li Sheng, Zhen-Yin Liu, Yi-Fu He, Kang-Sheng Gu, Guo-Wu Wu, Weibo Wang, Fu-Jun Zhang, W. Qiu, Jun Guo, Jie-Er Ying, H. Pan, Hui-Ting Xu, Yuan Yuan, Yuan-Song Bai, Zheng-Hua Wang, Jiye Xu, Xuehong Zhao, Hao Liu, Xi-Zhi Zhang, Wenxiang Dai, Hong-Yan Xu, Ming Liu, Lin Xie, Yong Tang, Jianying Jin, X. Qu, Xuefeng Fang, Ming-Wei Huang, Hao Chen, Zhendong Zheng, Ying Wang, Da-Qing Wang, Xiao-Qin Li, Guohua Yu, Hai-Yan Liu, Yong-Jian Zhou, Dian-Sheng Zhong, Shan Zeng, Mafei Kang, Meiqing Wang, Yong Gao, Wen-Xin Li, Ze-Jun Wang, Minghui Zhang, Jing-Hua Zhang, Qingshan Li, Shujuan Sun, A. Zang, Li-Zhu Lin, Ming Xie, Z. Zhuang, Tao Zhang, Zhifang Yao, Dongmei Lu, Wei Liu, Mingxiu Hu, Z. Wang, Bai-Yong Li, Michelle Y. Xia, Jia-Jia Zhang, Xiang-Ji Ying, D. Pardoll, Jia-Fu Ji

Nature Medicine

DOI

2025

Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial

Lin Shen, Yan-Qiao Zhang, Ziyu Li, Xiao-Tian Zhang, Xiang-Yu Gao, Bo Liu, Yu-Sheng Wang, Y. Ba, Ning Li, Ruixing Zhang, Jing-Dong Zhang, Ye Chen, Jian Chen, Mingzhu Huang, Yang Fu, Mu-Lin Liu, Zheng Liu, Jun Zhao, Wei Li, Jia Wei, Changzheng Li, Nong Xu, Zeng-Qing Guo, Bang-Wei Cao, Lian Liu, Peng Nie, Lixin Wan, Lili Sheng, Zhen-Yin Liu, Yi-Fu He, Kang-Sheng Gu, Guo-Wu Wu, Weibo Wang, Fu-Jun Zhang, W. Qiu, Jun Guo, Jie-Er Ying, H. Pan, Hui-Ting Xu, Yuan Yuan, Yuan-Song Bai, Zheng-Hua Wang, Jiye Xu, Xuehong Zhao, Hao Liu, Xi-Zhi Zhang, Wenxiang Dai, Hong-Yan Xu, Ming Liu, Lin Xie, Yongli Tang, Jianying Jin, X. Qu, Xuefeng Fang, Ming-Wei Huang, Hao Chen, Zhendong Zheng, Ying Wang, Da-Qing Wang, Xiao-Qin Li, Guohua Yu, Hai-Yan Liu, Yong-Jian Zhou, Dian-Sheng Zhong, Shan Zeng, Mafei Kang, Meiqing Wang, Yong Gao, Wen-Xin Li, Ze-Jun Wang, Minghui Zhang, Jing-Hua Zhang, Qingshan Li, Shujuan Sun, A. Zang, Li-Zhu Lin, Ming Xie, Z. Zhuang, Tao Zhang, Zhifang Yao, Dongmei Lu, Wei Liu, Mingxiu Hu, Z. Wang, Bai-Yong Li, Michelle Y. Xia, Jia-Jia Zhang, Xiang-Ji Ying, D. Pardoll, Jia-Fu Ji

Nature Medicine

DOI

2024

Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China.

Xiao-Hua Wu, Yang Sun, Hong-Ying Yang, Jing Wang, Hanmei Lou, Dan Li, Ke Wang, Hui Zhang, Tao Wu, Yu-Zhi Li, Chunyan Wang, Guiling Li, Yifeng Wang, Da-Peng Li, Ying Tang, M. Pan, Hong-Yi Cai, Weihu Wang, Bing Yang, Hua Qian, Qiu-Hong Tian, D. Yao, Ying Cheng, Bing Wei, Xiu-Min Li, Tao Wang, Min Hao, Xiaohong Wang, Tie-Jun Wang, J. Ran, Hong Zhu, Lijing Zhu, Xian-Ling Liu, Yun-Xia Li, Li-Hong Chen, Qingshan Li, Xiao-feng yan, Fei Wang, Hong-Bing Cai, Yun-Yan Zhang, Zhiqing Liang, Funan Liu, Yi Huang, B. Xia, Pengpeng Qu, Genhai Zhu, You-Guo Chen, Kun Song, Mei-Li Sun, Zheng-Zheng Chen, Qiang Zhou, Lina Hu, G. Abulizi, Hong Guo, Si-Hai Liao, Yijing Ye, Ping Yan, Qiu Tang, Guo-Ping Sun, Ting Liu, Dongmei Lu, Mingxiu Hu, Z. Wang, Bai-Yong Li, Michelle Y. Xia

The Lancet

DOI

2024

Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial.

W. Fang, Yuan-Yuan Zhao, Yongzhong Luo, Run-Xiang Yang, Yan Huang, Zhi-Yong He, Hui Zhao, Ming-Jun Li, Kai Li, Qi-Bin Song, Xiao-Bo Du, Yulan Sun, Wei Li, Fei Xu, Zhi-Yu Wang, Kunning Yang, Yun Fan, Bao-Gang Liu, Hong-Yun Zhao, Ying Hu, L. Jia, Shen Xu, T. Yi, D. Lv, Hai-Tao Lan, Mengxia Li, Wen-Hua Liang, Yong-Sheng Wang, Hui Yang, Yu-Ming Jia, Yuan Chen, Junguo Lu, Ji-Feng Feng, Chun-Ling Liu, Ming Zhou, Jian-Ya Zhou, Xian-Ling Liu, N. Zhou, Mingming He, Xiao-Rong Dong, Hualin Chen, Yong-Xing Chen, Haichuan Su, Xiao-Ling Li, Zhihong Zhang, Lei Yang, Ying Cheng, Li-Kun Chen, X. Hou, Yu Zhang, Jun Guo, Zhen Wang, Hong Lu, Di Wu, W. Feng, Wen Li, Jianan Huang, Yan Wang, Xia Song, Jie-Wen Peng, Laiyu Liu, Yu-Biao Guo, Wen-Ting Li, Dongmei Lu, Mingxiu Hu, Z. Wang, Bai-Yong Li, Michelle Y. Xia, Li Zhang

Journal of the American Medical Association (JAMA)

DOI

2024

Ebronucimab in Chinese Patients with Hypercholesterolemia---A Randomized Double-Blind Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Ebronucimab.

Yan-Yan Zhang, Zhaohui Pei, Bei-Jian Chen, Yanling Qu, Xiaolin Dong, Binge Yu, Guoqin Wang, Fang Xu, Dongmei Lu, Zhimei He, Ben-Chao Chen, Lei Ma, M. Wang, Bai-Yong Li, Michelle Y. Xia, B. Zheng, Y. Huo

Pharmacological Research

DOI

2023

Predictive value of machine learning for breast cancer recurrence: a systematic review and meta-analysis

Dongmei Lu, Xiaozhou Long, Wenjie Fu, Bo Liu, Xing Zhou, Shaoqin Sun

Journal of Cancer Research and Clinical Oncology

DOI

2020

“线上”“线下”混合式“金课”教学模式的探索——以“语文教学设计与技能训练”课程为例

路冬梅

《嘉兴大学学报》

2012

关于构建现代口语交际教学内容的思考

路冬梅

《教学与管理》

2012

提高小学语文教育质量的关键点

路冬梅

《课外语文》

2012

小学语文多媒体教学的优势及不足

路冬梅

《课外语文》

2011

中韩语言表达差异的文化分析

路冬梅

《新闻爱好者》

DOI

2004

从建构主义知识观角度看语文教学

路冬梅，王双云

《开封文化艺术职业学院学报》

2004

教师隐喻分析的启示

路冬梅

《开封文化艺术职业学院学报》

2004

论多元智力理论的教学意义

路冬梅

《教育探索》

2001

我省初中素质教育的困惑及对策研究

路冬梅

《开封文化艺术职业学院学报》

2000

论张爱玲小说的内审意识

路冬梅

《开封文化艺术职业学院学报》

1999

跨世纪中学教师素质结构研究

路冬梅，石弘，周建莉，张爱新，苏菊萍

《开封文化艺术职业学院学报》

1999

关于中学语文教师继续教育教学内容和课程设置的研究报告

李恒方，郭建平，冯庆堂，路冬梅，时学伟

《开封文化艺术职业学院学报》

1997

上好作文教学的起始课

路冬梅

《开封文化艺术职业学院学报》

1993

感受美·欣赏美·创造美——谈中学语文教学中的美育教育

路冬梅

《开封文化艺术职业学院学报》

1992

寓道于文,文道统一——谈中学语文教学中的思想教育

路冬梅

《开封文化艺术职业学院学报》

路冬梅

精选作品

期刊论文

TRIM28 orchestrates SUMO-ubiquitin crosstalk to stabilize PPARG and drive bladder cancer progression

Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China.

The impact of body mass index on the treatment response to neoadjuvant chemotherapy in patients with breast cancer: A systematic review and meta-analysis

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.

Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial

CDCA3-MYC positive feedback loop promotes bladder cancer progression via ENO1-mediated glycolysis

Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.

Cadonilimab in advanced cervical cancer: the COMPASSION-16 trial - Authors' reply.

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial.

Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)

First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial

Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial

Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China.

Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial.

Ebronucimab in Chinese Patients with Hypercholesterolemia---A Randomized Double-Blind Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Ebronucimab.

Predictive value of machine learning for breast cancer recurrence: a systematic review and meta-analysis

“线上”“线下”混合式“金课”教学模式的探索——以“语文教学设计与技能训练”课程为例

关于构建现代口语交际教学内容的思考

提高小学语文教育质量的关键点

小学语文多媒体教学的优势及不足

中韩语言表达差异的文化分析

从建构主义知识观角度看语文教学

教师隐喻分析的启示

论多元智力理论的教学意义

我省初中素质教育的困惑及对策研究

论张爱玲小说的内审意识

跨世纪中学教师素质结构研究

关于中学语文教师继续教育教学内容和课程设置的研究报告

上好作文教学的起始课

感受美·欣赏美·创造美——谈中学语文教学中的美育教育

寓道于文,文道统一——谈中学语文教学中的思想教育